Integrin αVβ6 Autoantibodies in PSC and IBD: Diagnostic and Pathogenic Insights

Overview

Anti-integrin αVβ6 autoantibodies are highly prevalent in ulcerative colitis (UC) and primary sclerosing cholangitis with IBD (PSC-IBD), with moderate correlation to intestinal disease activity. These autoantibodies are less frequent in Crohn’s disease and other cholestatic liver diseases, and are absent in healthy controls, suggesting a disease-specific role.

Background

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease often associated with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC). Integrin αVβ6 is an epithelial adhesion protein implicated in tissue remodeling and repair. Recent studies identified IgG autoantibodies against integrin αVβ6 strongly linked to UC, but their presence and significance in PSC and other liver diseases remained unclear. Understanding anti-αVβ6 autoantibodies may clarify disease mechanisms and improve diagnostic accuracy in PSC-IBD.

Data Highlights

Key Findings

• Anti-αVβ6 autoantibodies are present in 91% of UC patients and 73% of PSC-IBD patients, indicating strong association with these conditions.
• Only 17% of Crohn’s disease patients and 39% of PSC patients without IBD show anti-αVβ6 positivity, suggesting specificity for UC and PSC-IBD.
• Anti-αVβ6 autoantibodies are absent in healthy controls, secondary sclerosing cholangitis, and metabolic dysfunction-associated steatotic liver disease.
• Integrin αVβ6 expression is selectively upregulated in disease-associated epithelia of both bile ducts and colon in PSC patients.
• Anti-αVβ6 levels moderately correlate with intestinal disease activity in PSC-IBD but only weakly with biliary disease activity.
• Anti-αVβ6 autoantibodies may persist even after proctocolectomy, indicating potential ongoing immune activity independent of clinically manifest IBD.

Clinical Implications

Detection of anti-αVβ6 autoantibodies can aid in distinguishing PSC-IBD and UC from other inflammatory and cholestatic liver diseases, potentially serving as a diagnostic biomarker. Their correlation with intestinal disease activity suggests utility in monitoring disease progression or response to therapy. Persistence after proctocolectomy highlights the need for continued surveillance in PSC patients even after surgical intervention.

Conclusion

Anti-integrin αVβ6 autoantibodies are key markers and possible contributors to epithelial pathology in PSC-IBD and UC. Their selective presence and correlation with intestinal inflammation underscore their potential role in disease pathogenesis and clinical management.

References

1. Kuwada et al. 2022 -- Identification of Anti-Integrin αVβ6 Autoantibodies in Ulcerative Colitis
2. German PSC-IBD Cohort Study 2024 -- Integrin αVβ6 Autoantibodies in PSC and IBD